Who to call at TELA Bio, Inc., and when
Fundz watches for the moments TELA Bio, Inc. starts buying, and tells you who to reach.
- An alert the day TELA Bio, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at TELA Bio, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at TELA Bio, Inc.. With Fundz connected, it knows.
TELA Bio, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
telabio.comAI Executive Summary
AI-powered analysis of 8-K filing content
TELA Bio's Board increased its size from six to seven members on October 31, 2025, appointing William Plovanic as a Class I director with a term expiring at the 2026 Annual Meeting, and granting him options on 17,550 shares and an RSU award for 11,925 shares. This is a routine board expansion that adds a healthcare equity research professional with medical device operating experience.
Key Takeaways
The Board expanded from six to seven members and appointed William Plovanic, 56, as a Class I director with a term expiring at the 2026 Annual Meeting of Stockholders.
Plovanic is Managing Director, Healthcare Equity Research at Canaccord Genuity LLC (since May 2020), covering medical technology sectors including cardiovascular, diabetes, and neuromodulation.
3 more takeaways
Related Filings (11)
11 more filings from TELA Bio, Inc. in the last 90 days
Filing Overview
What This Means
TELA Bio, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.